🇺🇸 LLY — Eli Lilly and Company

Salud Compra
← Volver

Precio actual

1.417,99 USD

Máx. histórico

1.417,99

0 días

Split 2:1 del 16/10/1997

Caída desde máximo

En máximo

Rango 52 semanas

850,51 – 1.449,68

Variación hoy

+0,61%

Cierre anterior

1.409,38

Rango de hoy

1.401,59 – 1.445,96

Volumen hoy

3.622.682

Peor caída histórica

-68,26%

08/08/2000 → 05/03/2009

Recuperado en 2064 días

Volatilidad anualizada ⓘ

27,61%

Información
Nombre completo
Eli Lilly and Company
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
50.000
PER ⓘ
46,02 (puede no estar actualizado)
Dividend yield
0,49% (puede no estar actualizado)
Precio objetivo analistas
1.442,09 USD (puede no estar actualizado)
Primera cotización
01/06/1972
Precio actualizado
hace 7 horas
Sobre la empresa

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Dividendos repartidos Total últimos 12 meses: 6,6900 USD · Yield: 0,47%
Fecha de pago Importe por participación
14/08/2026 1,7300 USD
15/05/2026 1,7300 USD
13/02/2026 1,7300 USD
14/11/2025 1,5000 USD
15/08/2025 1,5000 USD
16/05/2025 1,5000 USD
14/02/2025 1,5000 USD
15/11/2024 1,3000 USD
15/08/2024 1,3000 USD
15/05/2024 1,3000 USD
14/02/2024 1,3000 USD
14/11/2023 1,1300 USD
14/08/2023 1,1300 USD
12/05/2023 1,1300 USD
14/02/2023 1,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
16/10/1997 2:1
21/12/1995 2:1
01/05/1989 2:1
30/01/1986 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
18/03/2019 123,99 125,35 123,50 125,24 +1,05% 1,49% 16.052.200
15/03/2019 123,10 124,16 121,96 123,94 +0,70% 1,79% 47.331.000
14/03/2019 124,98 124,98 122,51 123,08 -0,99% 1,98% 42.768.700
13/03/2019 124,60 130,75 123,16 124,31 +0,66% 6,09% 68.139.300
12/03/2019 123,50 124,02 122,68 123,50 +0,00% 1,09% 8.077.600
11/03/2019 122,80 124,91 122,51 123,50 -2,53% 1,95% 61.771.200
08/03/2019 126,37 126,98 125,25 126,70 +0,28% 1,37% 50.169.800
07/03/2019 126,41 127,19 125,13 126,34 -0,27% 1,63% 60.615.600
06/03/2019 128,75 128,79 125,39 126,68 -1,41% 2,64% 74.822.500
05/03/2019 128,40 128,87 126,72 128,49 +0,81% 1,67% 53.212.600
04/03/2019 130,51 130,51 125,34 127,46 -1,07% 3,96% 59.468.600
01/03/2019 127,25 129,42 126,58 128,84 +2,02% 2,23% 43.290.900
28/02/2019 125,52 127,77 125,20 126,29 +0,49% 2,05% 36.023.600
27/02/2019 124,49 126,48 124,08 125,68 +0,81% 1,93% 32.135.600
26/02/2019 123,86 125,16 123,32 124,67 +0,63% 1,49% 20.790.900
25/02/2019 124,10 124,67 123,47 123,89 -0,09% 0,97% 13.682.400
22/02/2019 122,73 124,74 122,65 124,00 +1,04% 1,70% 19.574.000
21/02/2019 122,06 123,76 121,80 122,72 +0,05% 1,61% 20.798.700
20/02/2019 122,38 123,05 121,61 122,66 +0,43% 1,18% 19.880.300
19/02/2019 121,31 123,33 121,30 122,13 -0,29% 1,67% 17.861.300
15/02/2019 121,18 122,48 120,40 122,48 +1,43% 1,72% 10.366.400
14/02/2019 118,94 121,25 118,80 120,75 +0,92% 2,06% 17.847.000
13/02/2019 119,60 120,28 118,11 119,65 +0,13% 1,81% 12.738.600
12/02/2019 117,76 119,90 117,50 119,49 +1,25% 2,04% 6.975.500
11/02/2019 119,20 119,94 117,04 118,01 -1,33% 2,43% 7.203.100
08/02/2019 117,73 121,43 117,45 119,60 +1,79% 3,38% 16.195.100
07/02/2019 119,00 119,33 116,86 117,50 -1,48% 2,08% 7.935.000
06/02/2019 118,67 120,82 117,74 119,27 -0,96% 2,60% 7.421.000
05/02/2019 120,72 121,74 120,40 120,43 +0,22% 1,11% 8.832.400
04/02/2019 121,21 121,84 118,69 120,17 -0,60% 2,60% 4.518.400